Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of
cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the cannabis plant
formulated for oral consumption, in healthy adults. The study will utilize a within-subjects,
placebo-controlled, double-blind, ascending-dose design.Upon enrollment, participants will
complete 5 oral dosing conditions (placebo, 25, 50, 100, and 200 mg CBG). Each condition will
consist of a single acute drug exposure, followed by an 8-hour period to evaluate acute
pharmacodynamic and pharmacokinetic drug effects. This work will provide novel data on the
pharmacokinetics, pharmacodynamic effects, and safety of acute oral CBG dose administration
in humans.